Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cantor Fitzgerald
McKesson
Teva
McKinsey
Merck
Daiichi Sankyo
Baxter
Argus Health

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090233

« Back to Dashboard

NDA 090233 describes BENZTROPINE MESYLATE, which is a drug marketed by Fresenius Kabi Usa, Hikma Farmaceutica, Luitpold, Navinta Llc, Aspen Global Inc, Chartwell Rx, Epic Pharma Llc, Invagen Pharms, Lannett Co Inc, Leading Pharma Llc, Oxford Pharms, Pliva, Quantum Pharmics, Usl Pharma, and Vintage, and is included in twenty-seven NDAs. It is available from twenty-nine suppliers. Additional details are available on the BENZTROPINE MESYLATE profile page.

The generic ingredient in BENZTROPINE MESYLATE is benztropine mesylate. There are six drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the benztropine mesylate profile page.
Summary for 090233
Tradename:BENZTROPINE MESYLATE
Applicant:Fresenius Kabi Usa
Ingredient:benztropine mesylate
Patents:0
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 090233
Medical Subject Heading (MeSH) Categories for 090233
Suppliers and Packaging for NDA: 090233
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BENZTROPINE MESYLATE benztropine mesylate INJECTABLE;INJECTION 090233 ANDA Nexus Pharmaceuticals Inc 14789-300 E 14789-300-02
BENZTROPINE MESYLATE benztropine mesylate INJECTABLE;INJECTION 090233 ANDA Fresenius Kabi USA, LLC 63323-970 E 63323-970-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1MG/ML
Approval Date:Jul 28, 2009TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKinsey
Daiichi Sankyo
Deloitte
Citi
AstraZeneca
US Department of Justice
US Army
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.